Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials

BACKGROUND: Whereas there are many pharmacological interventions prescribed for patients with advanced anaplastic lymphoma kinase (ALK)- rearranged non-small cell lung cancer (NSCLC), comparative data between novel generation ALK-tyrosine kinase inhibitors (TKIs) remain scant. Here, we indirectly co...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Hao-chuan, Liu, Yi-hong, Ding, Kai-lin, Liu, Yu-feng, Zhao, Wen-jie, Zhu, Yan-juan, Chang, Xue-song, Chen, Ya-dong, Xiao, Zhen-zhen, Yu, Ya-ya, Zhou, Rui, Zhang, Hai-bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620528/
https://www.ncbi.nlm.nih.gov/pubmed/34836510
http://dx.doi.org/10.1186/s12885-021-08977-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620528/
https://www.ncbi.nlm.nih.gov/pubmed/34836510
http://dx.doi.org/10.1186/s12885-021-08977-0

Ejemplares similares